TNXPEUR does not currently have enough recent insider (Form 4) trading activity to compute a convergence signal against its 13F institutional flows.
13F data as of 2024-06-30 quarterly filings. Note: many large institutions file close to the 45-day post-quarter deadline, so early-quarter flow figures can shift substantially as more filings arrive.
Insider Trading (Form 4)
Form 144 Pre-Sale Notices
No Form 144 planned sale filings in the last 90 days
Beneficial Ownership (13D/13G)
No Schedule 13D/13G filings for this ticker
Material Events (8-K)
No Form 8-K filings for this ticker
CUSIP
890260854
FAQ
Who are the top institutional investors holding TONIX PHARMACEUTICALS HOLDIN (TNXPEUR)?
Major stakeholders currently include Rosalind Advisors, Inc. ($19.6K), Twin Lakes Capital Management, LLC ($1.0). Based on the latest 13F filings, there are a total of 2 tracked investment funds and institutions maintaining positions in TNXPEUR.
What is the overall institutional sentiment toward TNXPEUR recently?
Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $2.2M, driven by 0 managers accumulating shares while 11 reduced their exposure.
Which institutions have been selling or reducing their TNXPEUR positions?
In the latest period, 0 funds trimmed their holdings, and 11 managers completely exited their positions. The aggregate reported sell value was $831.8K.
Are there any notable investors adding TNXPEUR to their portfolios?
No tracked institutions opened new positions or added to their existing holdings in TNXPEUR during the last reporting period.
Related Stocks
Trending Institutional Adds
The most-added stocks by 13F institutions this quarter